Skip to main content

These studies are for people who are recently diagnosed with HIV and have not started taking medications known as Antiretroviral Therapy (ART). For more information about Acute HIV please click here.

A5354

Goal Analyze the effects of starting Antiretroviral Therapy (ART) at different stages of acute HIV infection on HIV reservoirs and specific immune responses associated with HIV.
Who is eligible to participate Men and women older than 18 years of age with acute HIV infection.
Medication FDA-approved Genvoya
Duration 72 weeks
Compensation Visits – $25.00, Optional procedure visits – up to $250, Total – approximately $500. Travel & parking compensation are offered as well.

PHI 05

Goal Treatment of Acute HIV infection with one tablet once a day.
Who is eligible to participate Men and women older than 18 years of age with acute HIV infection.
Medication Fixed-dose combination of Dolutegravir and Epzicom
Duration 5 years (medication provided for 2 years)
Compensation

A5378

Goal To evaluate the safety and tolerability of a monoclonal antibody, VRC07-523LS, in people who have never been treated for HIV (treatment naive).
Who is eligible to participate  HIV infected men and women 18-70 years old who have never received Antiretroviral Therapy (ART).
Medication Monoclonal antibody, VRC07-523LS, administered through a single infusion
Duration 48 weeks
Compensation Visits – $50, Infusion visit with PK (specific kind of blood draw visit) – $150. Total – up to $1,350. Travel & parking compensation are offered as well.